Randomized controlled trial of clopidogrel to prevent primary arteriovenous fistula failure in hemodialysis patients

A Ghorbani, M Aalamshah, H Shahbazian, A Ehsanpour, A Aref, A Ghorbani, M Aalamshah, H Shahbazian, A Ehsanpour, A Aref

Abstract

The optimal vascular access for chronic maintenance hemodialysis is the arteriovenous fistula (AVF). Several studies suggest a role for antiplatelet agents in the prevention of primary AVF failure. A double-blind, randomized trial was conducted to assess the efficacy and safety of clopidogrel in hemodialysis patients. Ninety three patients were randomized to receive 75 mg/daily of clopidogrel or placebo. The treatment was initiated 7-10 days prior to scheduled access surgery and continued up to six weeks postoperatively, and then patients were monitored for six months. The primary outcome was AVF failure eight weeks after fistula creation. With a permuted block randomization schedule, 46 patients received clopidogrel and 47 patients received control placebo. The primary AVF failures at two months were 21.6% in placebo group and 5.2% in clopidogrel group (P = 0.03). The hazard ratio for the incidence of primary AVF failure was 0.72 (CI 95%, 0.41-1.01). Analysis of covariables indicated that this effect occurred principally as a result of clopidogrel administration. First hemodialysis from newly created AVF in clopidogrel group was significantly more successful than placebo group (P = 0.008). No life-threatening adverse event or severe bleeding was recorded in both groups. Clopidogrel seems to be effective and safe for prevention of primary AVF failure in hemodialysis patients.

Keywords: Arteriovenous fistula; clopidogrel; hemodialysis; primary AVF failure; vascular surgical procedures.

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations 2006 updates hemodialysis adequacy peritoneal dialysis adequacy vascular access. Am J Kidney Dis. 2006;48:S192–200.
    1. Woods JD, Port FK. The impact of vascular access for hemodialysis on patient morbidity and mortality. Nephrol Dial Transplant. 1997;12:657–9.
    1. Asif A, Roy-Chaudhury P, Beathard GA. Early arteriovenous fistula failure: A logical proposal for when and how to intervene. Clin J Am Soc Nephrol. 2006;1:332–9.
    1. Asif A, Cherla G, Merrill D, Cipleu CD, Briones P, Pennell P. Conversion of tunneled hemodialysis catheter consigned patients to arteriovenous fistula. Kidney Int. 2005;67:2399–407.
    1. Allon M, Robbin M. Increasing arteriovenous fistula in hemodialysis patients: Problems and solutions. Kidney Int. 2002;62:1109–24.
    1. Miller PE, Tolwani A, Luscy CP, Deierhoi MH, Bailey R, Redden DT, et al. Predictors of adequacy of arteriovenous fistulas in hemodialysis patients. Kidney Int. 1999;56:275–80.
    1. Beathard GA, Arnold P, Jackson J, Litchfield T. Aggressive treatment of early fistula failure. Kidney Int. 2003;64:1487–94.
    1. Roy-Chaudhury P, Kelly BS, Zhang J, Narayana A, Desai P, Melham M, et al. Hemodialysis vascular access dysfunction: From pathophysiology to novel therapies. Blood Purif. 2003;21:99–110.
    1. Andrassy K, Malluche H, Bornefeld H, Comberg M, Ritz E, Jesdinsky H, et al. Prevention of p.o. clotting of av. cimino fistulae with acetylsalicyl acid: Results of a prospective double blind study. Klin Wochenschr. 1974;52:348–9.
    1. Janicki K, Dmoszynska A, Janicka L, Stettner S, Jesipowicz J. Influence of antiplatelet drugs on occlusion of arteriovenous fistula in uraemic patients. Int Urol Nephrol. 1992;24:83–9.
    1. Michie D, Wombolt D. Use of sulfinpyrazone to prevent thrombus formation in arteriovenous fistulas and bovine grafts of patients on chronic hemodialysis. Curr Ther Res. 1977;22:196–204.
    1. Albert F. Prevention of early thrombus formation in arteriovenous fistulae. Dial Transplant. 1981;10:167C.
    1. Gröntoft KC, Mulec H, Gutierrez A, Olander R. Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis. Scand J Urol Nephrol. 1985;19:55–7.
    1. Gröntoft KC, Larsson R, Mulec H, Weiss LG, Dickinson JP. Effects of ticlopidine in AV-fistula surgery in uremia: Fistula Study Group. Scand J Urol Nephrol. 1998;32:276–83.
    1. Fiskerstrand CE, Thompson IW, Burnet ME, Williams P, Anderton JL. Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis. Artif Organs. 1985;9:61–3.
    1. Janicki K, Janicka L, Dmoszynska A, Marczewski K, Smarz I. Effects of ticlopidine on platelet activity and occlusion of arteriovenous fistulas in IPD patients. Dial Transplant. 1994;23:576–9.
    1. Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM. Anti-platelet therapy in graft thrombosis: Results of a prospective, randomized, double-blind study. Kidney Int. 1994;45:1477–83.
    1. Roy-Chaudhury P, Sukhatme VP, Cheung AK. Hemodialysis vascular access dysfunction: A cellular and molecular viewpoint. J Am Soc Nephrol. 2006;17:1112–7.
    1. Feldman HI, Kobrin S, Wasserstein A. Hemodialysis vascular access morbidity. J Am Soc Nephrol. 1996;7:523–35.
    1. Da Silva AF, Escofet X, Rutherford PA. Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. Cochrane Database Syst Rev. 2003;2:CD002786.
    1. Yevzlin AS, Conley EL, Sanchez RJ, Young HN, Becker BN. Vascular access outcomes and medication use: A USRDS study. Semin Dial. 2006;19:535–9.
    1. Kaufman JS, O'Connor TZ, Zhang JH, Cronin RE, Fiore LD, Ganz MB, et al. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol. 2003;14:2313–21.
    1. Kooistra M, van Es A, Marx J, Hertsig M, Struyvenberg A. Low-dose aspirin does not prevent thrombovascular accidents in low-risk haemodialysis patients during treatment with recombinant human erythropoietin. Nephrol Dial Transplant. 1994;9:1115–20.
    1. Dember LM, Kaufman JS, Beck GJ, Dixon BS, Gassman JJ, Greene T, et al. Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial. Clin Trials. 2005;2:413–22.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa